MRTX | Mirati Therapeutics, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	58.54 - 58.99
52 Week Range	27.30 - 64.41
Beta	0.72
Implied Volatility	33.01%
IV Rank	0.19%
Day's Volume	20,956,839
Average Volume	1,778,618
Shares Outstanding	70,147,696
Market Cap	4,117,669,755
Sector	Healthcare
Industry	Biotechnology
IPO Date	2013-07-15

Valuation
Profitability
Growth
Health
P/E Ratio	-4.82
Forward P/E Ratio	N/A
EPS	-12.18
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	587
Country	USA
Website	MRTX

Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; and Sitravatinib, an investigational spectrum-selective kinase inhibitor that is in Phase 3 clinical trial for the treatment of NSCL cancer, as well as a KRAS G12D inhibitor program, which is in preclinical development. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.

MRTX's peers: ALLK, ALLO, APLS, ARGX, ARQT, ARWR, AUTL, BBIO, BCRX, BGNE, BHVN, BTAI, CGEN, CVAC, EXEL, GMAB, IMAB, INVA, IOVA, ITOS, KOD, LEGN, RARE, RLAY, RPRX, SAGE, SANA, SRPT, SWTX, VRNA, ZNTL

*Chart delayed

Analyzing fundamentals for MRTX we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is very bad and Health is passable. For more detailed analysis please see MRTX Fundamentals page.

Watching at MRTX technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, but short-term trend is bearish. More technicals details can be found on MRTX Technicals page.